Trimetazidine protects isolated rat hearts against ischemia-reperfusion injury in an experimental timing - Dependent manner

Basic Research in Cardiology

Volumn 100, Issue 2, 2005, Pages 154-160

  Pantos, Constantinos ^a   Bescond Jacquet, Anne ^c   Tzeis, Stylianos ^a   Paizis, Ioannis ^a   Mourouzis, Iordanis ^a   Moraitis, Panagiotis ^a   Malliopoulou, Vassiliki ^a   Politi, Eustathia D ^a   Karageorgiou, Hariklia ^a   Varonos, Dennis ^a   Cokkinos, Dennis V ^b  

^a UNIVERSITY OF ATHENS   (Greece)

^b ONASSIS CARDIAC SURGERY CENTER   (Greece)

^c IRIS Institut de Recherches Internationales Servier   (France)

Author keywords

Ischemia reperfusion injury; MAPK kinases; Metabolism; Trimetazidine

Indexed keywords

LACTATE DEHYDROGENASE; MITOGEN ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN; TRIMETAZIDINE;

ANIMAL EXPERIMENT; ARTICLE; CELL CYCLE S PHASE; DOSE RESPONSE; ENZYME ACTIVITY; ENZYME RELEASE; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE PRESSURE; HEART MUSCLE ISCHEMIA; HEART MUSCLE PERFUSION; HEART MUSCLE REPERFUSION; HEART PROTECTION; ISOLATED HEART; LOW DRUG DOSE; MALE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN PHOSPHORYLATION; RAT; RAT STRAIN; REPERFUSION INJURY;

ANIMALS; CARDIOTONIC AGENTS; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; JNK MITOGEN-ACTIVATED PROTEIN KINASES; L-LACTATE DEHYDROGENASE; LACTIC ACID; MALE; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PERFUSION; PHOSPHORYLATION; RATS; RATS, WISTAR; TIME FACTORS; TRIMETAZIDINE; VENTRICULAR FUNCTION, LEFT; VENTRICULAR PRESSURE;

EID: 20144371323     PISSN: 03008428     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00395-004-0505-4     Document Type: Article

References (32)

1. Allibardi S, Chierchia SL, Margonato V, Merati G, Neri G, Dell'Antonio G, Samaja M (1998) Effects of trimetazidine on metabolic and functional recovery of postischaemic rat hearts. Cardiovasc Drugs Ther 12:543-549
2. Armstrong SC (2004) Protein kinase activation and myocardial ischemia/ reperfusion injury. Cardiovasc Res 61:427-436
3. Bogoyevitch M, Gillespie-Brown J, Ketterman A, Fuller SJ, Ben-Levy R, Ashworth A, Marshall CJ, Sugden PH (1996) Stimulation of the stress-activated mitogen-activated protein kinase sub-families in perfused heart: P38/RK mitogen-activated protein kinases and c-jun N-Terminal kinases are activated by ischaemia/reperfusion. Circ Res 79:162-173 1:CAS:528:DC%2BD38Xks12nsLc%3D
4. Boucher FR, Hearse DJ, Opie LH (1994) Effects of trimetazidine on ischaemic contracture in isolated perfused rat heart. J Cardiovasc Pharmacol 24:45-49
5. Cokkinos DV (2001) Can metabolic manipulation reverse myocardial dysfunction? Eur Heart J 22:2138-2139
6. El Banani H, Bernard M, Baetz D, Cabanes E, Cozzone P, Lucien A, Feuvray D (2000) Changes in intracellular sodium and pH during ischaemia-reperfusion are attenuated by trimetazidine; comparison between low-and zero flow ischaemia. Cardiovasc Res 47:688-696
7. Hausenloy DJ, Yellon DM (2004) New directions for protecting the heart against ischemia-reperfusion injury: Targeting the reperfusion injury salvage kinase (RISK)-pathway. Cardiovasc Res 61:448-460
8. Griffin JL, White LT, Lewandowski ED (2000) Substrate-dependent proton load and recovery of stunned hearts during pyruvate dehydrogenase stimulation. Am J Physiol Heart Circ Physiol 279(1):H361-H367
9. Kantor PF, Lucien A, Kozak R, Lopaschuk GD (2000) The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long chain 3-ketoacyl coenzyme A thiolase. Circ Res 86:580-588
10. Knight RJ, Buxton DB (1996) Stimulation of c-Jun kinase and mitogen-activated protein kinase by ischaemia and reperfusion in the perfused rat heart. Biochem Biophys Res Commun 218:83-88
11. Kudej RK, White LT, Kudej AB, Vatner SF, Lewandowski ED (2002) Brief increase in carbohydrate oxidation after reperfusion reverses myocardial stunning in conscious pigs. Circulation 106:2836-2841
12. Lavanchy N, Martin J, Rossi A (1987) Antischaemic effects of trimetazidine: 31P-NMR spectroscopy in the isolated rat heart. Arch Int Pharmacodyn Ther 286:97-110
13. Liu B, Clanachan AS, Schulz R, Lopaschuk GD (1996) Cardiac eficiency is improved after ischaemia by altering both the source and fate of protons. Circ Res 79:940-948
14. Lopaschuk GD (1998) Treating ischaemic heart disease by pharmacologically improving cardiac energy metabolism. Am J Cardiol 82:14K-17K
15. Mackay K, Mochly-Rosen D (1999) An inhibitor of p38 mitogen-activated protein kinase protects neonatal cardiac myocytes from ischaemia. J Biol Chem 274 (10):6272-6279 10.1074/jbc.274.10.6272
16. Marais E, Genade S, Huisamen B, Strijdom JG, Moolman JA, Lochner A (2001) Activation of p38 MAPK induced by a multi-cycle ischaemic preconditioning protocol is associated with attenuated p38 MAPK activity during sustained ischaemia and reperfusion. J Mol Cell Cardiol 33:769-778 1:CAS:528:DC%2BD3MXitFyls7o%3D
17. Marzilli M (2003) Cardioprotective effects of trimetazidine: A review. Curr Med Res Opin 19 (7):661-672
18. Maupoil V, Rochette L, Tabard A, Clauser P, Harpey C (1990) Direct measurement of free radical generation in isolated rat heart by electron paramagnetic resonance spectroscopy: Effect of trimetazidine. Adv Exp Med Biol 264:377-382
19. McVeigh JJ, Lopaschuk GD (1990) Dichloroacetate stimulation of glucose oxidation improves recovery of ischemic rat hearts. Am J Physiol 259:H1079-H1085
20. Minners J, van der Boss EJ, Yellon DM, Schwalb H, Opie LH, Sack MN (2000) Dinitrophenol, cyclosporin A, and trimetazidine modulate preconditioning in the isolated rat heart: Support for a mitochondrial role in cardioprotection. Cardiovasc Res 47:68-73
21. Opie LH (2003) Preconditioning and metabolic anti-ischaemic agents. Eur Heart J 24:1854-1856
22. Pantos C, Malliopoulou V, Mourouzis I, Karamanoli E, Paizis I, Steimberg N, Varonos D, Cokkinos DV (2002) Long term thyroxine administration protects the heart in a similar pattern as ischaemic preconditioning. Thyroid 12:325-329
23. Pantos C, Malliopoulou V, Mourouzis I, Sfakianoudis K, Tzeis S, Doumba P, Xinaris Ch, Cokkinos AD, Carageorgiou H, Varonos D, Cokkinos DV (2003a) Propylthiouracil induced hypothyroidism is associated with increased tolerance of the isolated rat heart to ischaemia-reperfusion. J Endocrinol 178(3):427-435
24. Pantos C, Malliopoulou V, Paizis I, Moraitis P, Mourouzis I, Tzeis S, Karamanoli E, Cokkinos DD, Carageorgiou H, Varonos D, Cokkinos DV (2003b) Thyroid hormone and cardioprotection; study of p38 MAPK and JNKs during ischaemia and at reperfusion in isolated rat heart. Mol Cell Biochem 242:173-180
25. Pantos C, Malliopoulou V, Mourouzis I, Moraitis P, Tzeis S, Thempeyioti A, Paizis I, Cokkinos AD, Carageorgiou H, Varonos D, Cokkinos DV (2003c) Involvement of p38 MAPK and JNK in the heat stress induced cardioprotection. Bas Res Cardiol 98:158-164
26. Pantos C, Malliopoulou V, Varonos D, Cokkinos DV (2004) Thyroid hormone and phenotypes of cardioprotection Basic Res Cardiol 99:101-120
27. Racey-Burns LA, Burns AH, Summer WR, Shepherd RE (1989) The effects of dichloroacetate on the isolated no flow arrested rat heart. Life Sci 44(26):2015-2023
28. 2+ regulation by trimetazidine during cardiac cell acidosis. Cardiovasc Drugs Ther 1:677-686
29. Stanley WC, Marzilli M (2003) Metabolic therapy in the treatment of ischaemic heart disease: The pharmacotherapy of trimetazidine. Fundamental Clinical Pharmacol 17:133-145
30. Taegtmeyer H, King LM, Jones BE (1998) Energy substrate metabolism, myocardial ischaemia, and targets for pharmacotherapy. Am J Cardiol 82:54K-60K
31. White LT, O'Donnell JM, Griffin J, Lewandowski ED (1999) Cytosolic redox state mediates post ischaemic response to pyruvate dehydrogenase stimulation. Am J Physiol 277:H626-H634
32. Yellon DM, Downey JM (2003) Preconditioning the myocardium: From cellular physiology to clinical cardiology. Physiol Rev 83:1113-1151